 The prevention of thrombus formation in the fibrillating atrium by anticoagulation has been shown to be effective; however, adverse bleeding events can occur with both warfarin even in the therapeutic range and NOAC. The frequency of any major or minor bleeding during NOAC treatment is approximately 15-18 per year; severe bleeding can lead to hospitalization or even death. 